EVALUASI DOSIS ASAM VALPROAT YANG DIGUNAKAN PADA PASIEN EPILEPSI ANAK DI RSUD SLEMAN YOGYAKARTA

• Main Authors: , HERNINGTYAS NAUTIKA LINGGA, , Prof. Dr. Lukman Hakim, M. Sc., Apt.
• Format: Theses and Dissertations NonPeerReviewed
• Published: [Yogyakarta] : Universitas Gadjah Mada 2013
• Subjects: ETD
• Online Access: https://repository.ugm.ac.id/122789/; http://etd.ugm.ac.id/index.php?mod=penelitian_detail&sub=PenelitianDetail&act=view&typ=html&buku_id=62895
• Institution: Universitas Gadjah Mada

Epilepsy is a chronic disease in neurology and the second most common disease after stroke. Epilepsy cases in Indonesia is at least 700,000-1,400,000 cases with accretion of 70,000 new cases each year and estimated 40-50% of prevalence occurred in children. Valproic acid is anti-epileptic drug that is widely used in Indonesia especially in children. It belongs to the medicine with a narrow therapeutic index which requires monitoring in the drug levels in plasma and dose adjustments to prevent toxic effects. This study aims to determine the estimated value of valproic acid concentration in serum and clinical outcomes in child patients with epilepsy seen from seizure-free duration at RSUD Sleman Yogyakarta. This study was a retrospective with design descriptive observational study. Subject in research was child patients with epilepsy who received valproic acid therapy in the period of January 2010-December 2012 aged 1 to 18 years, boys and girls who were routinely controlled for at least 6 consecutive months. Clinical outcomes were observed through the duration of the seizure-free which is devided into 2, ie <6 months (unfavorable outcome), and � 6 months (a good outcome). The results study of 99 patients met the inclusion criteria in the group of age less than or equal to 5 years as much as 27.28%, and 36.36% in the group of age >5-12 years and >12-18 years. From the calculation, average estimated value of valproic acid concentrations in serum for girls group, Css max as much as 86,32±49,25 mg/L and Css min 33,26±22,06 mg/L, in boys group Css max as much as 94,91±44,72 mg/L and Css min 38,57±20,72 mg/L. Clinical outcomes was assessed based on the duration of seizure-free patients showed in the group with monotherapy as much as 52,33% gave a good outcome and 47,67% gave a poor outcome. In group with polytherapy as much as 61,54% gave a good outcome and 38,46% gave a poor outcome.